Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.82+0.05 (+0.74%)
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Arvinas total assets
Total assets on the balance sheet at the end of each period.
Arvinas's total assets was $675.10M at Jun 30, 2026. For fiscal 2025 it was $717.90M, down 34.2% from the year before. The highest annual figure on record is $1.58B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $717.90M | -34.2% |
| FY2024 | Dec 31, 2024 | $1.09B | -16.3% |
| FY2023 | Dec 31, 2023 | $1.30B | +2.8% |
| FY2022 | Dec 31, 2022 | $1.27B | -19.8% |
| FY2021 | Dec 31, 2021 | $1.58B | +120.5% |
| FY2020 | Dec 31, 2020 | $717.40M | +137.8% |
| FY2019 | Dec 31, 2019 | $301.64M | +51.4% |
| FY2018 | Dec 31, 2018 | $199.28M | +198.1% |
| FY2017 | Dec 31, 2017 | $66.85M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $675.10M | -25.8% |
| Q1 FY2026 | Mar 31, 2026 | $647.50M | -35.3% |
| Q4 FY2025 | Dec 31, 2025 | $717.90M | -34.2% |
| Q3 FY2025 | Sep 30, 2025 | $844.30M | -27.7% |
| Q2 FY2025 | Jun 30, 2025 | $909.30M | -28.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.00B | -17.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.09B | -16.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.17B | +10.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.28B | +18.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.21B | +3.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.30B | +2.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.06B | -20.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.08B | -23.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.18B | -21.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.27B | -19.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.33B | -16.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.41B | +118.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.49B | +118.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.58B | +120.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.60B | +490.1% |
| Q2 FY2021 | Jun 30, 2021 | $644.03M | +145.3% |
| Q1 FY2021 | Mar 31, 2021 | $681.77M | +141.4% |
| Q4 FY2020 | Dec 31, 2020 | $717.40M | +137.8% |
| Q3 FY2020 | Sep 30, 2020 | $271.95M | +30.1% |
| Q2 FY2020 | Jun 30, 2020 | $262.58M | +52.6% |
| Q1 FY2020 | Mar 31, 2020 | $282.45M | +51.4% |
| Q4 FY2019 | Dec 31, 2019 | $301.64M | +51.4% |
| Q3 FY2019 | Sep 30, 2019 | $209.09M | +111.4% |
| Q2 FY2019 | Jun 30, 2019 | $172.05M | +157.4% |
| Q1 FY2019 | Mar 31, 2019 | $186.57M | – |
| Q4 FY2018 | Dec 31, 2018 | $199.28M | – |
| Q3 FY2018 | Sep 30, 2018 | $98.89M | – |
| Q4 FY2017 | Dec 31, 2017 | $66.85M | – |
See a number that looks wrong?